Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]
Awaiting development
Reference number: GID-TA11326
Expected publication date: TBC
Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.